Condition: Primary Photoreceptor Disease · Retinitis Pigmentosa (RP) · Usher Syndrome · Sponsor: BlueRock Therapeutics
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
This description comes directly from the study's public registry record.
Patient Engagement · 1-877-380-3931 · clinicaltrials@bluerocktx.com
Always discuss trial participation with your own doctor first.
| University of Southern California /Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| University of Miami, Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| Mid Atlantic Retina/ Wills Eye | Philadelphia, Pennsylvania, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06789445